Cortexyme presents an update and baseline data from the phase 2/3 gain trial of atuzaginstat at ctad 2020, the clinical trials on alzheimer's disease conference

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical stage biopharmaceutical company pioneering potential therapeutics for alzheimer's and other degenerative diseases, announced the presentation of data demonstrating that in a subset of samples analyzed to date, a very high proportion of the adults with mild to moderate alzheimer's disease (ad) enrolled in the ongoing phase 2/3 gain trial of atuzaginstat have biomarker profiles consistent with ad, and all pat
QNCX Ratings Summary
QNCX Quant Ranking